Palisade Bio, Inc. (NASDAQ:PALI) Receives $10.20 Consensus PT from Analysts

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have earned an average rating of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $10.20.

A number of brokerages recently weighed in on PALI. Stifel Nicolaus began coverage on Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price objective on the stock. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Wolfe Research assumed coverage on Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Finally, HC Wainwright assumed coverage on Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target on the stock.

Institutional Investors Weigh In On Palisade Bio

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in shares of Palisade Bio by 5,780.7% in the 4th quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after buying an additional 1,538,832 shares during the last quarter. State Street Corp bought a new stake in shares of Palisade Bio in the 4th quarter valued at about $1,513,000. Jane Street Group LLC bought a new stake in shares of Palisade Bio in the 4th quarter valued at about $808,000. Balyasny Asset Management L.P. bought a new stake in shares of Palisade Bio in the 4th quarter valued at about $765,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Palisade Bio in the 4th quarter valued at about $565,000. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Price Performance

Shares of PALI stock opened at $1.93 on Friday. The firm has a market capitalization of $335.01 million, a P/E ratio of -1.91 and a beta of 1.52. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.86. The stock’s fifty day simple moving average is $2.00 and its 200 day simple moving average is $1.93.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, equities research analysts expect that Palisade Bio will post -0.21 EPS for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.